Identification of Serine-875 as an Inhibitory Phosphorylation Site in the Calcium-Sensing Receptor.

DOI:
10.1124/mol.119.116178

Document Version
Final published version

Link to publication record in Manchester Research Explorer

Citation for published version (APA):

Published in:
Molecular pharmacology

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.
Identification of Serine-875 as an Inhibitory Phosphorylation Site in the Calcium-Sensing Receptor

Lenah S. Binmahfouz, Patricia P. Centeno, Arthur D. Conigrave, and Donald T. Ward

Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom (L.S.B., P.P.C., D.T.W.); King Abdulaziz University, Jeddah, Saudi Arabia (L.S.B.); and Charles Perkins Center, School of Life and Environmental Sciences, University of Sydney, Camperdown, New South Wales, Australia (A.D.C.)

Received February 8, 2019; accepted May 20, 2019

ABSTRACT

The calcium-sensing receptor (CaS) is the principal controller of extracellular calcium (Ca^{2+}) homeostasis and is inhibited in vitro and in vivo by protein kinase C (PKC)-mediated phosphorylation at CaS^T888. However, PKC inhibition enhances signaling even in CaSs lacking Thr-888, suggesting that an additional inhibitory site exists. An apparently equivalent PKC regulatory site in metabotropic glutamate receptor 5 (Ser-839) aligns not with CaS^T888 but instead with CaS^S875, which was not previously considered to be a PKC site. CaS^{S875A} (nonphosphorylatable) exhibited significantly enhanced Ca^{2+} sensitivity of both intracellular Ca^{2+} mobilization and extracellular signal-regulated kinase 1/2 activation, whereas the phosphomimetic CaS^{S875D} mutant exhibited a loss of function. The CaS^{S875A/T888A} double mutant exhibited even greater Ca^{2+} sensitivity than CaS^T888A alone, a response no longer enhanced by PKC inhibition. Finally, when expressed in CaS lacking its extracellular domain, the CaS^{S875A/T888A} double mutation elicited maximal activation even under control conditions, but remained sensitive to negative allosteric modulation [N-(2-hydroxy-3-(2-cyano-3-chlorophenoxy)propyl)-1,1-dimethyl-2-(2-ethyl)ethylamine] or Ca^{2+} removal. Therefore, we have now identified CaS^{S875} as the missing PKC phosphorylation site that, together with CaS^T888, shapes the CaS signaling that underpins Ca^{2+} homeostasis. Together with the inactive form of the CaS extracellular domain, these sites attenuate Ca^{2+} sensitivity to attain appropriate physiologic Ca^{2+} sensing.

SIGNIFICANCE STATEMENT

Serine-875 represents the missing inhibitory PKC phosphorylation site in CaS that in tandem with Thr-888 controls receptor activity.

Introduction

The calcium-sensing receptor (CaS) is the principal controller of extracellular calcium (Ca^{2+}) homeostasis, suppressing both parathyroid hormone secretion and renal calcium reabsorption in response to high Ca^{2+} concentration. When first cloned, CaS was predicted to contain five protein kinase C (PKC) consensus sequences: two in the first and third intracellular loops, Thr-646 and Ser-794; and three in the CaS intracellular tail, Thr-888, Ser-895, and Ser-915 (Garrett et al., 1995; Bai et al., 1998). Previous results from this laboratory and others (Bai et al., 1998; Davies et al., 2007; Young et al., 2014) have shown that one of these residues, CaS^T888, represents the key phosphorylation site responsible for PKC-mediated inhibition of CaS-mediated intracellular Ca^{2+} (Ca^{2+}) mobilization in vitro. In humans, mutation of CaS^{T888} to a nonphosphorylatable methionine produces a gain-of-function CaS, resulting in autosomal dominant hypocalcaemia (Lazarus et al., 2011). Bai et al. (1998) reported that while the other four known PKC sites play little or no role in mediating PKC’s functional effect, CaS^{T888} cannot be the sole determinant of the PKC effect. Furthermore, in the current laboratory, it was shown that CaS^{S875A} still causes Ca^{2+} oscillations in some cells (at least in the presence of 2 mM Ca^{2+}), and PKC activation with the phorbol ester phorbol 12-myristate 13-acetate (PMA) elicits a partial inhibitory effect in CaS^{S875A} (Davies et al., 2007) and CaS^{S875D} (Lazarus et al., 2011) expressing cells. Together, these findings have suggested the existence of an additional PKC site in CaS.

The idea of PKC-mediated inhibition of class C G protein-coupled receptors (GPCRs) came initially not from CaS but from the structurally homologous metabotropic glutamate receptor 5 (mGluR5) (Dale et al., 2001; Hermans and Challiss, 2001), with Ser-839 being shown to be the most likely mediator of the PKC response (Kim et al., 2005). Indeed, mutation of Ser-839 in mGluR5 to alanine (mGluR5^S839A) was shown to prevent Ca^{2+} oscillations in HeLa cells (Kim et al., 2005). Interestingly, mGluR5^S839A does not align with CaS^{T888} or indeed with any of the known PKC consensus sequences in the CaS. Instead, it aligns with CaS^{S875}, a residue not

ABBRVIATIONS: Ca^{2+}, intracellular Ca^{2+}; Ca^{2+}, extracellular Ca^{2+}; CaS, calcium-sensing receptor; CaS^WT, wild-type calcium-sensing receptor; ECD, extracellular domain; ERK1/2, extracellular signal-regulated kinase 1/2; GFX, GF109203X (bisindolylmaleimide I); GPCR, G protein-coupled receptor; HEK-293, human embryonic kidney 293; ICD, intracellular domain, mGluR5, metabotropic glutamate receptor 5; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; TMD, transmembrane domain.
Previously considered likely to be a PKC site. In support of this idea, Huttlin et al. (2010) reported murine phospho-proteomic data that included evidence of phosphorylation at CaS<sup>S875</sup>. Furthermore, while only five CaS residues were originally proposed to be PKC consensus sequences (Garrett et al., 1995), the NetPhos database (NetPhos 3.1 Server; http://www.cbs.dtu.dk/services/NetPhos-3.1/) predicts CaS as having as many as 15 potential PKC sites, including both CaS<sup>S875</sup> and CaS<sup>T888</sup>. Therefore, the aim of this study was to evaluate the effect of mutating Ser-875 on CaS-mediated signaling to assess whether it likely represents the missing PKC site (Bai et al., 1998) in the intracellular domain (ICD). This was investigated both in wild-type CaS (CaS<sup>WT</sup>) and also in a CaS construct (Rho-C-hCaS) lacking most of the extracellular domain ([ECD], residues 1–599), thus leaving just the seven-transmembrane domain (TMD) and N-terminal ICD as described previously (Zhao et al., 1999).

**Materials and Methods**

**Cell Culture.** Human embryonic kidney 293 (HEK-293) cells transfected with CaS<sup>WT</sup> were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% heat-inactivated FBS (Sigma-Aldrich, Gillingham, UK). To avoid cell death, gain-of-function mutant cell lines were routinely cultured in low Ca<sup>2+</sup> RPMI (containing 0.42 mM Ca<sub>Cl</sub><sub>2</sub>) instead of Dulbecco’s modified Eagle’s medium (containing 1.8 mM Ca<sub>Cl</sub><sub>2</sub>).

**Mutagenesis.** Mutations were introduced into the wild-type human parathyroid CaS by site-directed mutagenesis using the QuickChange lightning site-directed mutagenesis kit in accordance with the manufacturer’s instructions (Agilent Technologies Ltd., Cheadle, UK). HEK-293 cells were then transiently transfected with wild-type or mutant receptors using FuGENE6 (Promega, Southampton, UK). For stable expression, vectors were linearized prior to transfection and the resulting CaS-expressing cells were selected using Hygromycin (Duchefa Biochemie). Clonal cell lines were then established. The Rho-C-hCaS mutant was obtained from R. Mun (The Charles Perkins Centre, The University of Sydney, Camperdown, Australia) having been initially generated by Zhao et al. (1999). All mutations were subsequently verified by the DNA sequencing facility at The University of Manchester.

**Immunoblotting.** CaS expression was demonstrated by immunoblotting as described previously (Ward et al., 1998) using an anti-CaS mouse monoclonal antibody (ADD; amino acids 214–235 of human CaS; Fisher Scientific, Loughborough, UK). In brief, cells were lysed on ice in a detergent-containing HEPES buffer supplemented with protease inhibitors and 1 mM N-ethylmaleimide. The lysate was centrifuged at 12,000 g (for 10 minutes at 4°C) and the supernatant was solubilized in Laemmli buffer at 65°C.

**Intracellular Calcium Imaging.** CaS-induced Ca<sup>2+</sup> mobilization was assayed by epifluorescence microscopy as described previously (Davies et al., 2007) after loading cells with Fura-2 AM (Life Technologies Ltd., Paisley, UK). CaS-transfected cells were exposed to increasing concentrations of Ca<sup>2+</sup> in experimental buffer [20 mM HEPES (pH 7.4), 125 mM NaCl, 4 mM KCl, 0.5 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub>, and 5.5 mM glucose] at room temperature to compare relative Ca<sup>2+</sup> sensitivities between the receptors. The coverslips were mounted in a perfusion chamber (Warner Instruments, Hamden, CT) and fluorescence visualized using a Nikon Diaphot inverted microscope equipped with a digital camera charge-coupled device.

**Extracellular Signal-Regulated Kinase 1/2 Phosphorylation.** Extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation in CaS-transfected cells was assayed as described previously (Ward et al., 2002). In brief, cells were exposed to various concentrations of Ca<sup>2+</sup> in experimental buffer at 37°C for 10 minutes prior to lysis on ice in detergent-containing buffer supplemented with protease and phosphatase inhibitors. ERK1/2 phosphorylation was then determined by semiquantitative immunoblotting using a phosphospecific antibody (Cell Signaling Technology).

**Data and Statistical Analysis.** The data are presented as mean ± S.D. (for pEC<sub>50</sub> variance; shown as insets in the graphs) or mean ± S.E.M. (for precision of the individual responses, shown graphically). Statistical significance between pEC<sub>50</sub> values (P values < 0.05) was determined by Student’s unpaired/paired t test or one-way ANOVA followed by Dunnett’s or Tukey’s multiple comparisons test as appropriate (GraphPad Prism version 7). For the Ca<sup>2+</sup> assay, the area under the curve of the Fura-2 ratios (MetaFlour) for all cells in a field of view over a given time range was calculated using GraphPad Prism (version 7) with resulting curves produced using a sigmoidal dose-response (variable slope) equation.

**Results**

**Effect of CaS<sup>S875A</sup> and CaS<sup>S875D</sup> Phospho-Mutations on Ca<sup>2+</sup>-Induced Ca<sup>2+</sup> Mobilization.** The key inhibitory PKC site in mGlur5 (mGlur5<sup>S839</sup>) aligns in the CaS not with the recognized inhibitory PKC site CaS<sup>T888</sup> (Bai et al., 1996; Davies et al., 2007) but instead with CaS<sup>S875</sup> (Supplemental Fig. 1), which has not been previously considered to be a PKC site (Garrett et al., 1995; Bai et al., 1996). Thus, to examine the potential role of CaS<sup>S875</sup> phosphorylation on receptor signaling, this residue was mutated either to a nonphosphorylatable alanine residue (CaS<sup>S875A</sup>) or to a phosphomimetic aspartic acid residue (CaS<sup>S875D</sup>) in CaS<sup>WT</sup>. Subsequently, both mutated receptors were transiently transfected into HEK-293 cells, and CaS-induced Ca<sup>2+</sup> mobilization was measured in response to increasing concentrations of Ca<sup>2+</sup> (0.5–10 mM). As shown in Fig. 1, CaS<sup>S875A</sup> was a gain-of-function mutation showing enhanced receptor sensitivity to Ca<sup>2+</sup> relative to CaS<sup>WT</sup> (EC<sub>50</sub>, 2.3 CaS<sup>S875A</sup> vs. 3.5 mM CaS<sup>WT</sup>; P < 0.01). A similar gain of function was seen in HEK-293 cells stably expressing the CaS<sup>S875A</sup> mutation (Supplemental Figs. 2 and 3). In contrast, CaS<sup>S875D</sup> exhibited decreased Ca<sup>2+</sup> sensitivity relative to CaS<sup>WT</sup>, indicating that it is a loss-of-function mutation (EC<sub>50</sub>, 4.7 CaS<sup>S875D</sup> vs. 3.5 mM CaS<sup>WT</sup>; P < 0.01) (Fig. 1).

**CaS<sup>T888A</sup> and CaS<sup>S875A</sup> Mutations Enhance Ca<sup>2+</sup>-Induced ERK1/2 Phosphorylation.** The relative responses of CaS<sup>T888A</sup> and CaS<sup>S875A</sup> on Ca<sup>2+</sup>-stimulated ERK1/2 phosphorylation were next compared with CaS<sup>WT</sup> control responses using HEK-293 cells expressing each receptor stably. In agreement with the Ca<sup>2+</sup> mobilization data, CaS<sup>S875A</sup> enhanced Ca<sup>2+</sup>-induced phosphorylated ERK1/2 activation relative to CaS<sup>WT</sup> control (EC<sub>50</sub>, 1.9 CaS<sup>S875A</sup> vs. 3.8 mM CaS<sup>WT</sup>; P < 0.01) (Fig. 2). A similar gain of function was seen, as expected, in CaS<sup>T888A</sup>-expressing cells (EC<sub>50</sub>, 2.2 CaS<sup>T888A</sup> vs. 4.4 mM CaS<sup>WT</sup>; P < 0.01). Equal protein loading on the blots was confirmed by uniform β-actin expression. An equivalent gain of function for Ca<sup>2+</sup> mobilization by the CaS<sup>T888A</sup> stably expressing cells is shown in Supplemental Fig. 4. There is evidence that forward trafficking of the CaS can be modulated by its association with 14-3-3 protein under the control of CaS<sup>S899</sup> phosphorylation (Grant et al., 2011, 2015). As such, it is important to consider whether CaS<sup>S875</sup> phosphorylation affects functional signaling directly or merely as a determinant of cell surface localization. To examine this, HEK-293 cells were transiently transfected with CaS<sup>WT</sup>, CaS<sup>S875A</sup>, and CaS<sup>T888A</sup>, and the membrane localization of
these receptors was then analyzed using a surface biotinylation assay. As shown in Supplemental Fig. 5 we saw no evidence of substantive changes in cell surface localization of receptors lacking Ser-875 or Thr-888. However, taken together these observations confirm that CaSS875A is a gain-of-function mutation, with a similar impact on Ca\textsuperscript{2+} -stimulated signaling responses to CaST888A.

**Effect of CaSS875A/T888A Double Mutation on Ca\textsuperscript{2+} Signaling.** Since both CaSS875A and CaST888A exhibited gain of function by two different experimental readouts, it was next decided to introduce both mutations in the same receptor to test whether their effects are additive. This question was asked since Bai et al. (1996) found that PKC inhibition could further enhance CaST888A signaling, suggesting that another PKC site may contribute additional receptor modulation. The resulting CaSS875A/T888A double mutant was tested for its effect on Ca\textsuperscript{2+} mobilization as previously detailed in both transiently (Supplemental Fig. 6) and stably transfected (Fig. 3) HEK-293 cells. In both cases, the doubly mutated CaSS875A/T888A exhibited significantly lower EC\textsubscript{50} values and increased sensitivity for Ca\textsuperscript{2+} than for the CaST888A mutant (stable, 1.8 CaSS875A/T888A vs. 2.4 mM CaST888A; \( P < 0.01 \)) (Fig. 3). It was further noted that the CaSS875A/T888A double mutant completely abolished Ca\textsuperscript{2+} oscillations, which CaST888A failed to do at lower Ca\textsuperscript{2+} concentrations.

Similar to its effect on Ca\textsuperscript{2+} mobilization, the CaSS875A/T888A double mutant also increased Ca\textsuperscript{2+} sensitivity of ERK1/2 phosphorylation compared with CaST888A alone (EC\textsubscript{50}, 2.5 vs. 206 Binmahfouz et al. Fig. 1. CaSS875 acts as an inhibitory phosphorylation site. Fura-2-loaded HEK-293 cells were transiently transfected with either (A) CaSWT (B) CaSS875A or (C) CaSS875D, and then exposed to increasing Ca\textsuperscript{2+} concentrations (0.5–10 mM) to determine the effect of the putative phosphorylation site CaSS875 on Ca\textsuperscript{2+} mobilization. The representative traces show the Ca\textsuperscript{2+} changes (Fura-2 ratio) in single cells from the field of view. The whole field-of-view changes in Ca\textsuperscript{2+} concentration are shown as concentration-effect curves in (D). ** \( P < 0.01 \) vs. CaSWT by one-way ANOVA with Dunnett’s post hoc test. Data are representative of three independent experiments (n ≥ 6 coverslips).

Fig. 2. CaST888A and CaSS875A mutations increase CaS-induced ERK1/2 phosphorylation. (A) HEK-293 cells were stably transfected with either CaSWT, CaST888A (i) or CaSS875A (ii), and then stimulated with various Ca\textsuperscript{2+} concentrations (0.5–5 mM) for 10 minutes to determine the effect of mutating the two phosphorylation sites on extracellular signal-regulated kinase (pERK) activation. Representative western blots indicating ERK1/2 phosphorylation, together with β-actin loading control, are shown above the resulting concentration-effect curves in each graph. ERK1/2 responses are expressed as a percentage of CaSWT maximal response in each experiment. ** \( P < 0.01 \) CaST888A vs. CaSS875A (n = 6 from three independent experiments) or CaSS875A vs. CaSWT (n = 7 from three independent experiments) pEC\textsubscript{50} values by unpaired \( t \) test, \( n ≥ 8 \) from three independent experiments. (B) CaS immunoblots showing similar receptor abundance between cell lines, with their protein loading equivalence confirmed by β-actin expression.
Ca²⁺ inhibited in cells expressing CaSS875A/T888A (EC₅₀, 7.5 vs. 3.2 mM) with respect to both Ca²⁺. The two panels show Ca²⁺ traces from representative single cells. The resulting concentration-effect curves are shown in (iii). *P < 0.01 for CaST888A vs. CaSS875A/T888A by unpaired t test; n ≥ 9 coverslips from three independent experiments. Equivalence of CaS abundance between cell lines is shown in (iv), with β-actin loading control. (B) Representative western blots showing ERK1/2 phosphorylation and β-actin immunoreactivity in the same cell lines as before, stimulated with various Ca²⁺ concentrations (0.5–5 mM) for 10 minutes. The resulting concentration-effect relationship is shown on the right. ERK1/2 responses are expressed as a percentage of CaST888A maximal response in each experiment. *P < 0.05 EC₅₀ values for CaS²⁺ vs. CaSS875A/T888A by unpaired t test; n ≥ 6 from three independent experiments.

To confirm that stable transfection with the double mutant receptor CaSS875A/T888A had not increased Gq-mediated Ca²⁺ mobilization in a nonspecific manner, the effect of carbachol on Ca²⁺ mobilization was also tested. Carbachol also elicits oscillatory Ca²⁺ mobilization in wild-type HEK-293 cells (Supplemental Fig. 7i), most likely via the muscarinic acetylcholine receptor (Atwood et al., 2011). However, the CaSS875A/T888A double mutant failed to increase carbachol sensitivity for Ca²⁺ mobilization, suggesting that CaSS875A/T888A gain of function is not due to a nonspecific increase in Gq-mediated Ca²⁺ mobilization or an artifact of transfection (Supplemental Fig. 7, ii–iv). Indeed, carbachol responsiveness was inhibited in cells expressing CaSS875A/T888A (EC₅₀, 7.5 vs. 3.2 μM CaS²⁺; P < 0.01). The cause of this reduced carbachol responsiveness was not investigated further.

**PKC Inhibition Fails to Further Enhance CaS²⁺ Mobilization**

Having confirmed that the double mutant CaSS875A/T888A exhibits significantly greater Ca²⁺ responsiveness than CaST888A alone, we next tested whether PKC inhibition could elicit additional signal enhancement suggestive of yet further PKC sites. For this, CaSS875A/T888A stably expressing cells were treated with or without bisindolylmaleimide I (GF109203X (GFX), 250 nM), a nonspecific PKC inhibitor, for 30 minutes, and then co-stimulated with increasing concentrations of Ca²⁺ (0.5–5 mM), with Ca²⁺ mobilization assayed as previously described (Fig. 4). For comparison, CaS²⁺ and CaSS875A/T888A cells were tested alongside one another in these experiments. As expected, GF109203X treatment significantly increased the sensitivity of both CaS²⁺ (EC₅₀ 6.5 control vs. 3.3 mM GFX; P < 0.001) and CaSS875A/T888A (EC₅₀ 2.4 control vs. 1.2 mM GFX; P < 0.001) for Ca²⁺. However, there was no difference in CaS-induced Ca²⁺ mobilization between CaSS875A/T888A double mutants treated without or with GF109203X; that is, they both increased CaS²⁺ sensitivity to a virtually identical extent (EC₅₀ 1.8 control vs. 1.7 mM GFX; P = 0.86). These data suggest that the positive effect of PKC inhibition can be replaced entirely by alanine mutation of both inhibitory phosphorylation sites, Ser-875 and Thr-888, indicating that Ser-875 is another PKC site.

**Effect of CaS²⁺ and CaSS875A Mutations on Rho-Ca²⁺ Mobilization**

Having established the dual inhibitory effect of CaS²⁺ and CaSS875A on CaS signaling, the role of both phosphorylation sites was next tested in the context of a CaS construct lacking the entire ECD (Rho-Ca²⁺) to assess their inhibitory effects on the TMD core of the receptor. The hypothesis was that if the ECD of the CaS is responsible for ligand-dependent activation (Bräuner-Osborne et al., 1999; Geng et al., 2016; Zhang et al., 2016), then relieving the PKC-mediated inhibitory constraints on the receptor might result in ligand-independent activation
activation of the CaS. In such a case, mutation of the inhibitory phosphorylation sites might enhance responsiveness even in a headless CaS.

Rho-C-hCaS lacks most of the ECD (residues 1–599); therefore, it contains only the 7TMD and the carboxy-terminal ICD with a stop codon at residue 903 as described previously (Zhao et al., 1999) (Supplemental Fig. 8A). To facilitate cell surface expression, the start of this truncated CaS was fused to 20 amino acid residues of the N-terminus of bovine rhodopsin (MNGTEGPNFYVPFSNKTGVV). First, Rho-C-hCaS was transiently transfected into HEK-293 cells, and then the effect of increasing Ca\(_{2+}\) concentrations (up to 10 mM) on Ca\(_{2+}\) mobilization was assayed as previously described. In contrast to CaSWT, which elicits oscillatory signaling, Rho-C-hCaS elicited only transient or sustained Ca\(_{2+}\) mobilization (Supplemental Fig. 8B). It should be noted that no Ca\(_{2+}\) mobilization was seen under these conditions in nontransfected HEK-293 cells (data not shown). Moreover, the effect of PKC inhibition on Rho-C-hCaS signaling was tested. For this, HEK-293 cells transiently transfected with either CaSWT or CaST888A were first exposed to 3 mM Ca\(_{2+}\) to elicit Ca\(_{2+}\) mobilization and then cotreated with 250 nM of GF102903X. Indeed, GF102903X enhanced Rho-C-hCaS-induced Ca\(_{2+}\) mobilization in response to 3 mM Ca\(_{2+}\) (P < 0.05) (Supplemental Fig. 8C).

Next, it was examined whether mutating Thr-888 and/or Ser-875 to alanine can also increase Rho-C-hCaS responsiveness. Compared with the Rho-C-hCaS control, the Rho-C-hCaST888A mutant was more sensitive to Ca\(_{2+}\) (EC\(_{50}\) 1.8 Rho-C-hCaST888A vs. 2.8 mM Rho-C-hCaS; P < 0.05) (Fig. 5A), similar to the effect of T888A in the full-length CaS (Supplemental Fig. 4). In contrast, Rho-C-hCaSS875A did not exhibit significantly enhanced receptor responsiveness compared with Rho-C-hCaS (EC\(_{50}\) 2.4 Rho-C-hCaSS875A vs. 2.8 mM Rho-C-hCaS; P = 0.18). Therefore, when expressed alone in the headless receptor, only T888A exhibits greater Ca\(_{2+}\) sensitivity.
Effect of Rho-C-hCaSS875A/T888A Double Mutation on Ca\textsuperscript{2+} Mobilization. Finally, despite the S875A mutation having no significant effect on Rho-C-hCaS responsiveness on its own, we investigated whether this mutation may potentiate the enhanced responsiveness seen with Rho-C-hCaSS888A when expressed in combination. Indeed, the Rho-C-hCaSS875A/T888A double mutant produced maximal Ca\textsuperscript{2+} mobilization even under baseline conditions (0.5 mM Ca\textsuperscript{2+}). However, this effect could be virtually abolished by cotreatment with the CaS negative allosteric modulator (calcilytic) N-(2-hydroxy-3-(2-cyano-3-chlorophenoxy)propyl)-1,1-dimethyl-2-(2-nephthyl)ethylamine (1 μM; *P < 0.001) (Fig. 6B). To determine whether the Rho-C-hCaSS875A/T888A double mutant is constitutively active, i.e., elicits continuous signaling even in the absence of an agonist, Ca\textsuperscript{2+} mobilization was tested using a buffer that was nominally free of Ca\textsuperscript{2+} and extracellular Mg\textsuperscript{2+} (*P < 0.001). Interestingly, introduction of 0.5 mM Mg\textsuperscript{2+} alone was sufficient to elicit cellular Ca\textsuperscript{2+} transients in some coverslips. Subsequent introduction of 0.5 mM Ca\textsuperscript{2+} restored maximal activation of the Rho-C-hCaSS875A/T888A double mutant. Thus, although Rho-C-hCaSS875A/T888A was not constitutively active, it exhibited substantially enhanced sensitivity to Ca\textsuperscript{2+} (i.e., with a presumed EC\textsubscript{50} < 0.5 mM) despite the absence of an ECD. Together, these data demonstrate the importance of PKC-mediated Ser-875 and Thr-888 phosphorylation in the control of CaS signaling.

Discussion

Initial sequence analysis of the human CaS predicted that only five of the intracellular serine/threonine residues were likely to be PKC phosphorylation sites: two in the first and third intracellular loops (Thr-646 and Ser-794) and three in the ICD (Thr-888, Ser-895, and Ser-915) of the receptor (Garrett et al., 1995; Bai et al., 1998). Previous results have shown that one of these, CaST888, represents the key phosphorylation site responsible for PKC-mediated inhibition of CaS-mediated Ca\textsuperscript{2+} mobilization (Bai et al., 1998; Davies et al., 2007; Young et al., 2014). However, it should be noted that the human CaS has in fact 54 serine and threonine residues in either its ICD or three intracellular loops, although no tyrosine residues (Garrett et al., 1995). The NetPhos database predicts that 40 of these sites reach the threshold for being potential phosphorylation sites for at least one out of a panel of 17 protein kinases (http://www.cbs.dtu.dk/services/NetPhos-3.1/). Interestingly, all of the serine/threonine residues in the juxtamembrane region of the ICD (residues 863–920) are predicted to be phosphorylation sites for one protein kinase or another, whereas in the later carboxyl-terminus few such residues are likely phosphorylation sites. In addition, this database predicts not five PKC sites in the CaS but 15 (including Ser-875), although it should also be noted that these predictions are based on primary sequence and do not take into account site accessibility or location. Nevertheless, current consensus site prediction databases indicate much greater scope for CaS phosphorylation than was considered when CaS was first cloned.

It has been suggested that where GPCRs have a variety of potential kinase consensus sequences, the precise pattern of phosphorylation on any given receptor could be quite different in different cellular contexts. The so-called phospho-barcode hypothesis posits that different patterns of phosphorylation could elicit distinct downstream signaling outcomes (Tobin et al., 2008; Yang et al., 2017). The barcode hypothesis was first devised by studying two GPCRs: the muscarinic acetylcholine receptor (Butcher et al., 2011) and the β2-adrenergic receptor (Nobles et al., 2011). The present findings indicate

![Fig. 6. Effect of CaSS875A/T888A double mutation on Rho-C-hCaS.](molpharm.aspetjournals.org)
that the CaS may also exhibit distinct phospho-barcodes in different cell types and/or following exposure to biased agonists or cotreatments with other GPCR agonists.

Consistent with the NetPhos database prediction and the current data, a phospo-proteomic study using mass spectrometry to detect phosphorylation sites in nine different organs from 3-week-old male mice has previously determined CaS$^{S875T}$ as a phosphorylation site in the kidney (Huttlin et al., 2010). This demonstrates that CaS$^{S875}$ is capable of being phosphorylated in vivo. In addition, sequence alignment analysis of the ICDs of the CaS with the structurally homologous mGLuR5 confirms that CaS Ser-875 is equivalent to the principal PKC phosphorylation site in mGLuR5, namely, Ser-839 (MEGA-X software) (Supplemental Fig. 1A). Therefore, the alignment of CaS$^{S875}$ and mGLuR5$^{S839}$ suggests that they share similar regulatory roles in the modulation of receptor signaling. Moreover, the amino acid conservation of the putative Ser-875 phosphorylation site was examined in the current study across a previously published multiple sequences alignment of 51 different vertebrate CaS species (Herberger and Loretz, 2013) using the free WebLogo analysis website (https://weblogo.berkeley.edu/logo.cgi). As reflected by the high WebLogo bit scores (Supplemental Fig. 1B), CaS$^{S875}$ is well conserved within different species. Overall, the conservation of Ser-875 is consistent with the phosphorylation site prediction and the strong functional role in CaS signaling. One important consideration regarding these phosphorylation sites is to determine whether they modulate signal transduction directly or instead by altering CaS cell surface localization (Breitwieser, 2013), as is apparently the case for CaS$^{S899}$ (Grant et al., 2015). In this regard, we did not see a significant difference in the surface biotinylation of CaS$^{S875A}$ or CaS$^{T888A}$ versus CaS$^{WT}$ receptors. Nevertheless, it would be helpful to have a more thorough analysis of the effect of these and other CaS phospho-site point mutations on receptor maturation, forward trafficking, agonist-driven insertion signaling, internalization, and desensitization. However, in the meantime the current data establish a clear link between residues CaS$^{S875}$ and CaS$^{T888}$ and CaS down-stream signaling.

In agreement with our previous study (Davies et al., 2007), CaS$^{T888A}$ elicits more sustained Ca$^{2+}$ mobilization than CaS$^{WT}$. However, at lower Ca$^{2+}$ concentrations (1.5–2.5 mM) Ca$^{2+}$ oscillations continued in some CaS$^{T888A}$-expressing cells. Young et al. (2002) did not observe such oscillations in CaS$^{T888A}$-expressing cells, although only 3 mM Ca$^{2+}$ was used to stimulate the receptor in that study, and in our experiments 3 mM Ca$^{2+}$ also elicited only sustained Ca$^{2+}$ mobilization with CaS$^{T888A}$. Significantly, the persistence of Ca$^{2+}$ oscillations in CaS$^{T888A}$-transfected cells suggests that this site alone cannot be the exclusive phosphorylation location controlling Ca$^{2+}$ oscillations (Davies et al., 2007), meaning that an additional signaling determinant is required.

In support of this idea, Bai et al. (1998) previously showed that PKC activation by PMA reduced the responsiveness of a mutant CaS, in which all five predicted PKC sites were eliminated. Moreover, PMA elicited a partial inhibitory effect in cells expressing CaS$^{T888A}$ (Davies et al., 2007) and CaS$^{T888S}$ (Lazarus et al., 2011). Because PMA increases the phosphorylation of serine/threonine residues, these preserved inhibitory effects could be explained by the presence of an additional, previously unidentified PKC site(s) on the CaS. As such, the current results indicate that Ser-875 is the previously unidentified PKC site. Specifically, CaS$^{S875A}$ with its nonphosphorylatable mutation enhanced signaling, whereas CaS$^{S875D}$ with its phosphomimetic mutation inhibited signaling. Furthermore, the CaS$^{S875A/T888A}$ double mutation further enhanced both Ca$^{2+}$-induced Ca$^{2+}$ mobilization and ERK1/2 phosphorylation more than for CaS$^{T888A}$ alone, whereas concomitant PKC inhibition had no further effect. To prove that CaS$^{S875}$ is a PKC site and then determine the ligand sensitivity of such phosphorylation, as was done for CaS$^{T888}$ (Davies et al., 2007; Mc Cormick et al., 2010), it will be necessary to raise a phospho-CaS$^{S875}$ specific antibody. However, our initial attempt to generate such an antibody proved unsuccessful, and thus we must rely instead on the mutagenesis studies reported herein, the new consensus predictions described previously, the alignment to mGLuR5$^{S839}$, and the previous murine proteomic data (Huttlin et al., 2010). On balance, we would argue that the simplest explanation of the current data is that CaS$^{S875}$ is a functionally important PKC site, in conjunction with CaS$^{T888}$. However, the possible involvement of other phosphorylation sites in the regulation of CaS function awaits determination.

That CaS$^{S875A/T888A}$ expression failed to enhance carbachol signaling supported the idea that the gain of function was CaS specific and not an artifact of transfection. However, the observation that CaS$^{S875A/T888A}$ expression, in fact, inhibited carbachol signaling is interesting. It is proposed that receptors exist in a conformational equilibrium between inactive and active states, and that G proteins have higher affinity for the active state of the receptor (Burstein et al., 1995). Since both CaS and the muscarinic acetylcholine receptor are Go$_a$ coupled, it seems feasible that they compete for the same Go$_a$-protein pool (Linderman, 2009), and thus perhaps Go$_a$ has sufficiently higher affinity for the hyperactive CaS$^{S875A/T888A}$ double mutant, such that fewer Go$_a$ proteins were available to elicit the carbachol response. This issue requires further study.

Consistent with Mun et al. (2004), the Rho-C-hCaS mutant was sensitive to increasing concentrations of Ca$^{2+}$, which further verified the existence of at least one Ca$^{2+}$-binding site in the 7TMD of the CaS (Hammerland et al., 1999; Hu et al., 2002; Ray and Northup, 2002). This confirmation of the functional activity of the Rho-C-hCaS mutant allowed the determination of the role of PKC phosphorylation sites in a functionally active CaS that was not subject to control by the ECD. Introducing the mutation T888A to Rho-C-hCaS increased its Ca$^{2+}$ sensitivity to that seen for the full-length CaS$^{T888A}$. Although Rho-C-hCaS$^{S875A}$ did not, on its own, enhance Ca$^{2+}$ sensitivity (we observed a trend in this direction), the Rho-C-hCaS$^{S875A/T888A}$ exhibited maximal Ca$^{2+}$ responsiveness even in control buffer. The response did not represent constitutive activity since Rho-C-hCaS increased its Ca$^{2+}$ sensitivity to that seen for the full-length CaS$^{T888A}$. Although Rho-C-hCaS$^{S875A}$ did not, on its own, enhance Ca$^{2+}$ sensitivity (we observed a trend in this direction), the Rho-C-hCaS$^{S875A/T888A}$ exhibited maximal Ca$^{2+}$ responsiveness even in control buffer. These findings suggest that the TMD/proximal ICD core of the CaS might be much more Ca$^{2+}$ sensitive than is generally appreciated, and that the inactive form of the ECD and activation of the two PKC phosphorylation sites arrest its responsiveness. In summary, the present study has identified CaS$^{S875}$ as a phosphorylation site that together with CaS$^{T888}$ acts as a negative controller of CaS signaling and maintains...
Ca\textsuperscript{2+}-stimulated Ca\textsuperscript{2+} oscillations that underpin CaS-mediated control of Ca\textsuperscript{2+} homeostasis.

Acknowledgments

The authors thank Dr. R. Mun (The Charles Perkins Centre, The University of Sydney, Camperdown, Australia) for providing the Rho-C-HCaS mutant construct and also Kathryn Bailey and Dr. Sarah Davies for technical assistance.

Authorship Contributions

Participated in research design: Binmahfouz, Conigrave, Ward.
Conducted experiments: Binmahfouz, Centeno.
Contributed new reagents or analytic tools: Conigrave, Ward.
Performed data analysis: Binmahfouz.
Wrote or contributed to the writing of the manuscript: Binmahfouz, Conigrave, Ward.

References

Kim CH, Braud S, Isaac JTR, and Roche KW (2005) Protein kinase C phosphorylation of the metabotropic glutamate receptor mGluR5 on Serine 839 regulates Ca\textsuperscript{2+} oscillations. J Biol Chem 280:25409–25415.
Young SH, Wu SY, and Rozengurt E (2002) Ca\textsuperscript{2+}-stimulated Ca\textsuperscript{2+} oscillations produced by the Ca\textsuperscript{2+}-sensing receptor require negative feedback by protein kinase C. J Biol Chem 277:46871–46876.

Address correspondence to: Dr. Donald T. Ward, Faculty of Biology, Medicine and Health, Michael Smith Building, The University of Manchester, Manchester M13 9PT, UK. E-mail: d.ward@manchester.ac.uk